ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
5
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
5,697
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Breakthrough Therapy Designation, Case study Brigatinib
Author(s):
Publication date:
2014
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Karger: Oncology
Data availability:
ScienceOpen disciplines:
Oncology & Radiotherapy
,
Medicine
Comments
Comment on this article
Sign in to comment
Similar content
5,697
Brigatinib activity in patients with ALK+ NSCLC and intracranial CNS metastases in two clinical trials
Authors:
SN Gettinger
,
D. Kim
,
M Tiseo
Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status
Authors:
RM HUBER
,
D.-W. Kim
,
M-J Ahn
…
Brigatinib is another treatment option for patients diagnosed with advanced
ALK
-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib
Authors:
Barbara Melosky
,
Parneet Cheema
,
Geoffrey Liu
See all similar